Anti-cancer therapy using a leptin antagonist and an inkt-cell activator

Dirk Elewaut; Koen Venken; Jan Tavernier; Lennart Zabeau; Eline Menu; Mérédis Favreau

Anti-cancer therapy using a leptin antagonist and an inkt-cell activator

Dirk Elewaut (Uitvinder), Koen Venken (Uitvinder), Jan Tavernier (Uitvinder), Lennart Zabeau (Uitvinder), Eline Menu (Uitvinder), Mérédis Favreau (Uitvinder)

Onderzoeksoutput: Patent

Samenvatting

The present invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of a leptin antagonist and an invariant natural killer T (iNKT) cell activator.

Originele taal-2	English
Octrooinummer	WO2017207040
Status	Published - 2017

Handle.net

Permanente koppeling

Andere bestanden en links

https://worldwide.espacenet.com/patent/search/family/056134312/publication/WO2017207040A1?q=WO2017207040

FWOTM771: Exosomale communicatie bij Multipel Myeloom: vriend of vijand?
Vanderkerken, K. (Administrative Promotor) & Faict, S. (Mandataris)
1/10/15 → 30/09/19
Project: Fundamenteel

Citeer dit

@misc{29187dbe6330430fb205d98d1fefc7f0,

title = "Anti-cancer therapy using a leptin antagonist and an inkt-cell activator",

abstract = "The present invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of a leptin antagonist and an invariant natural killer T (iNKT) cell activator.",

author = "Dirk Elewaut and Koen Venken and Jan Tavernier and Lennart Zabeau and Eline Menu and M{\'e}r{\'e}dis Favreau",

year = "2017",

language = "English",

type = "Patent",

note = "WO2017207040",

}

TY - PAT

T1 - Anti-cancer therapy using a leptin antagonist and an inkt-cell activator

AU - Elewaut, Dirk

AU - Venken, Koen

AU - Tavernier, Jan

AU - Zabeau, Lennart

AU - Menu, Eline

AU - Favreau, Mérédis

PY - 2017

Y1 - 2017

N2 - The present invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of a leptin antagonist and an invariant natural killer T (iNKT) cell activator.

AB - The present invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of a leptin antagonist and an invariant natural killer T (iNKT) cell activator.

UR - https://worldwide.espacenet.com/patent/search/family/056134312/publication/WO2017207040A1?q=WO2017207040

M3 - Patent

M1 - WO2017207040

ER -

Anti-cancer therapy using a leptin antagonist and an inkt-cell activator

Samenvatting

Handle.net

Andere bestanden en links

Vingerafdruk

Projecten

FWOTM771: Exosomale communicatie bij Multipel Myeloom: vriend of vijand?

Citeer dit